Novo Nordisk Board Reshuffle Names Sorensen

Novo Nordisk A/S (NVO) installed Lars Rebien Sorensen as chairman on Nov. 14, 2025, in a board reshuffle driven by the Novo Nordisk Foundation that sparked minority shareholder protest and coincided with management narrowing strategy and revising earnings guidance.

Foundation-Led Board Changes Raise Governance Concerns

At an extraordinary general meeting on Nov. 14, shareholders approved Sorensen as chairman, replacing several independent directors. The reshuffle was initiated by the Novo Nordisk Foundation, the company’s controlling shareholder, prompting minority investors to protest over governance and board independence.

Mikael Dolsten, a key research-and-development (R&D) leader, withdrew his candidacy on Nov. 13. The Foundation did not propose a replacement before the meeting and deferred nominating two additional board members to the incoming board, with a deadline set for March 2026.

The changes have intensified scrutiny over governance, R&D oversight, and strategic direction. Investors and governance experts view the reshuffle as a test of how the company will balance the Foundation’s influence with the board’s independence and its role overseeing a complex drug pipeline.

Strategy Narrowed as Earnings Guidance Revised

Novo Nordisk has lowered its earnings guidance, citing slower market growth and increased competition in the GLP-1 obesity-drug segment. Management is shifting away from aggressive mergers and acquisitions to focus on internal innovation and expanding in the U.S. market. The company withdrew its bid for Metsera Inc. as part of this strategic recalibration.

CEO Mike Doustdar has emphasized advancing the diabetes and obesity pipeline. No material regulatory approvals or government interventions were reported in connection with the board changes.

The incoming board faces a dual mandate: restore investor confidence in governance and ensure execution of the company’s R&D-driven plan for diabetes and obesity treatments.